<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<meta name="Generator" content="SAS Software Version 9.4, see www.sas.com">
<meta http-equiv="Content-type" content="text/html; charset=utf-8">
<title>SAS Output</title>
<style type="text/css">
<!--
.accessiblecaption
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.aftercaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.batch
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  padding: 7px;
}
.beforecaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.body
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  margin-left: 8px;
  margin-right: 8px;
}
.bodydate
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  text-align: right;
  vertical-align: top;
  width: 100%;
}
.bycontentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.byline
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.bylinecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.caption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.cell
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.container
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.contentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contentprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contents
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.contentsdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.contenttitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.continued
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  width: 100%;
}
.data
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.dataemphasis
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataemphasisfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataempty
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datafixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datastrong
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.datastrongfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.date
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.document
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.extendedpage
{
  background-color: #FFFFFF;
  border: 1pt solid #000000;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
  text-align: center;
}
.fatalbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.folderaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footer
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.frame
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.graph
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.header
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.headersandfooters
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.index
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.indexprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.indextitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.linecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.note
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notebanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.output
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.pageno
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  text-align: right;
  vertical-align: top;
}
.pages
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.pagesdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.pagesitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.pagesproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagesprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagestitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.paragraph
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.parskip
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.prepage
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitlefixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooter
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooteremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooteremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooterempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowfooterstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheader
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderemphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderemphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowheaderstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.systemfooter
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemtitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systitleandfootercontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.table
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.top_stacked_value
{
  padding-bottom: 1px;
  border: 0;
}
.middle_stacked_value
{
  padding-top: 1px;
  padding-bottom: 1px;
  border: 0;
}
.bottom_stacked_value
{
  padding-top: 1px;
  border: 0;
}
.titleandnotecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.titlesandfooters
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.usertext
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warnbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.l {text-align: left }
.c {text-align: center }
.r {text-align: right }
.d {text-align: right }
.j {text-align: justify }
.t {vertical-align: top }
.m {vertical-align: middle }
.b {vertical-align: bottom }
TD, TH {vertical-align: top }
.stacked_cell{padding: 0 }
-->
</style>
<script language="javascript" type="text/javascript">
<!-- 
function startup(){

}
function shutdown(){

}

//-->
</script>

</head>
<body onload="startup()" onunload="shutdown()" class="body">

<script language="javascript" type="text/javascript">
<!-- 
var _info = navigator.userAgent
var _ie = (_info.indexOf("MSIE") > 0
          && _info.indexOf("Win") > 0
          && _info.indexOf("Windows 3.1") < 0);
var _ie64 = _info.indexOf("x64") > 0

//-->
</script>

<div class="branch">
<a name="IDX"></a>
<table class="systitleandfootercontainer" width="100%" cellspacing="1" cellpadding="1" rules="none" frame="void" border="0" summary="Page Layout">
<tr>
<td class="c systemtitle">Adiponectin data set 2</td>
</tr>
</table><br>
<div>
<div align="center">
<table class="table" cellspacing="1" cellpadding="7" rules="none" frame="box" summary="Procedure Print: Data Set REF2.ADIPONECTIN_SORTED_2">
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="l header" scope="col">Title</th>
<th class="l header" scope="col">Research_Gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="l data">Obesity and inflammation: the linking mechanism and the complications</td>
<td class="l data">(A) Sustained inflammation is considered a strong risk factor =&gt; developing many diseases =&gt; CVD&#39;s, metabolic syndrome, diabetes + cancer. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Obesity =&gt; predisposes to a pro-inflammatory state =&gt; via increased inflammatory mediators =&gt; IL-6 and TNF-a + redn levels of adiponectin (which has anti-inflammatory function). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) TNF-a =&gt; overexpressed in overweight state + IL-6 =&gt; linked more to the obese state =&gt; influences =&gt; liver to synthesize + secrete CRP =&gt; feature of systemic inflammation. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Inflammatory state =&gt; reduced levels of adiponectin, =&gt; important implications on =&gt;  insulin sensitivity, reducing metabolic abnormalities + adjusting energy expediture. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Inflammatory state =&gt; vascular + endothelial dysfunction =&gt; characterized by decreased nitric oxide (NO) + elevated reactive oxygen species (ROS) =&gt; oxidative stress. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Both oxidative stress + inflammatory states =&gt; atherosclerosis, hypertension, alteration of metabolic markers =&gt; major adverse cardiovascular events. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="l data">Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY</td>
<td class="l data">(A) Present investigation of racial / ethnic contrast in adiponectin, insulin sensitivity + B-cell function in TODAY at randomization + over time =&gt; demonstrates; XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1. NHB =&gt; significantly lower total adiponectin, high molecular weight adiponectin (HMWA) + HMWA-to-total adiponectin ratio at baseline vs other groups. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 2. Treatment-associated change in HMWA over time =&gt; significantly different among the 3 racial groups  + lower percentage increase over the first 6 months in NHB. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 3. Early change in HMWA =&gt; 1st 6 months of treatment =&gt; significant independent predictor of progression to glycaemic failure. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 4. Baseline HMWA =&gt; did not predict glycaemic failure =&gt; NOR was it different between those who failed vs did not fail treatment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 5. Treatment-associated change in total + HMWA =&gt; significantly lower =&gt; those that failed treatment vs those who did not fail =&gt; irrespective of race / ethnicity. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  6. No racial / ethnic-related differences in insulin sensitivity + B-cell function at baseline + over time. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (C) TODAY study =&gt; obese youth + T2D =&gt; randomly assigned =&gt; metformin alone, metformin + rosiglitazone or metformin + lifestyle =&gt; glycaemic failure rates =&gt; higher in NHB (52.8%) vs NHW (36.6%) + H (45.0%) =&gt; race / ethnicity alone =&gt; significant effect beyond the treatment effect. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Racial / ethnic disparity =&gt; higher HbA1c in black vs white youth with T2D =&gt; reported in paediatric diabetes clinic. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) To probe the metabolic / hormonal mechns =&gt; potentially responsible for the racial / ethnic disparity =&gt; therapeutic failure rates in TODAY, we targeted; XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1. Adiponectin =&gt; because it is known to vary by race / ethnicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 2. Insulin sensitivity + B-cell function =&gt; well-established racial / ethnic contrast. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Adiponectin has anti-diabetic properties =&gt; suppresses hepatic glucose output + lowers systemic glucose concns, stimulates skeletal muscle glucose uptake + promotes B-cell function + survival. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Adiponectin concns =&gt; low  in obesity + states of IR, T2D + CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Adiponectin levels =&gt; youth T2D =&gt; significantly lower vs equally obese peers without diabetes + correlate +vely =&gt; insulin sensitivity + 1st phase insulin response + -vely with =&gt; proinsulin =&gt; insulin ratio in youth with / without diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (I) Adiponectin levels =&gt; prognostic value for diabetes course beyond currently recognized set of risk factors. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Racial / ethnic differences =&gt; adiponectin =&gt; previously described =&gt; youth + adults. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) NHB youth =&gt; signifcantly lower adiponectin concns vs white peers =&gt; irrespective of adiposity. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Studies of HMWA =&gt; similar racial / ethnic contrasts =&gt; adults. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Current study =&gt; NHB youth + T2D =&gt; significantly lower total adiponectin + HMWA concns =&gt; at time of randomization =&gt; TODAY =&gt; post-adjustment for higher BMI in NHB. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Additional novel findings =&gt; HMWA-to-total adiponectin ratio =&gt; significantly lower in NHB vs other two groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Baseline adiponectin =&gt; did NOT provide any prognostic value =&gt; glycaemic failure. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) Baseline adiponectin =&gt; neither predictor of glycaemic failure in Cox proportional hazards analysis NOR were baseline adiponectin levels different between failed vs not failed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Adiponectin levels in adults increase with treatment of diabetes + effect more pronounced with thiazolidiones. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Rosiglitazone =&gt; 4 - 8 mg/day =&gt; adiponectin levels increase by =&gt; 50 - 200% after 3 - 6 months in adults  with T2D =&gt; improvements in glycaemic control + insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Metformin treatment in adults with T2D =&gt; most but not all studies =&gt; no change in adiponectin levels. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Diabetes Prevention Program (DPP) =&gt; metformin intervention in impaired glucose tolerant adults =&gt; associated with a significant increase in adiponectin from baseline to 1 year. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Results on the effect of metformin treatment =&gt; adiponectin concns in youth =&gt; contradictory. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Some studies =&gt; no change in obese IR normoglycaemic adolescents =&gt; other studies =&gt; increases after 3 months of metformin 850 mg BD in youth with impaired glucose tolerance. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Trials combining metformin with lifestyle intervention in obese children + normal glucose tolerance =&gt; increase in adiponectin levels =&gt; after 3 + 6 months. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Studies in youth + T2D =&gt; change in adiponectin associated with metformin + thiazolidinedione =&gt; lacking. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Present investigation =&gt; total adiponectin + HMWA increased during the first 6 months in 3 racial / ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Metformin + rosiglitazone group =&gt; significantly larger increases over time vs metformin alone + metformin + lifestyle groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) This is in agreement with observations =&gt; adult T2D =&gt; consistent increases in adiponectin with rosiglitazone or thiazolidinedione treatment =&gt; not necessarily the case with metformin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) This investigation =&gt; important observation =&gt; treatment associated changes in HMWA =&gt; proportional to the effectiveness of treatment in preventing glycaemic failure (HR 0.55 total cohort, 0.52 in NHB, 0.58 in H + 0.63 in NHW). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Proportional hazards modelling =&gt; changes in total adiponectin + HMWA =&gt; remained significant determinants of progression to glycaemic failure, even after adjustment =&gt; baseline HbA1c + oDI =&gt; important determinants of glycaemic failure. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Treatment associated change in total adiponectin + HMWA =&gt; significantly lower =&gt; failed treatment vs not failed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Metformin + rosiglitazone group =&gt; larger increases in HMWA over time vs metformin alone + metformin + lifestyle groups =&gt; further support TODAY main outcome =&gt; combn of metformin + rosiglitazone  =&gt; superior to metformin =&gt; sustaining durable glycaemic control =&gt; glycaemic failure rates 38.6% vs 51.7% metformin vs 46.6% metformin + lifestyle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Collectively =&gt; novel observations =&gt; underscore =&gt; utility of adiponectin in youth T2D =&gt; biomarker of treatment response =&gt; predictive of glycaemic efficacy consistent with adult data. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Combined with the discovery =&gt; increase in HMWA =&gt; significantly lower in NHB vs H + NHW =&gt; provides explanation =&gt; higher therapeutic failure rates in NHB vs two other racial groups. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Remaining question =&gt; lower increase in HMWA in NHB =&gt; biological / genetic phenomenon OR inadequate treatment adherence. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Adherence to the medn regimen =&gt; defined by =&gt; pill count =&gt; did NOT differ by race / ethnicity</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="l data">Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study</td>
<td class="l data">(A) Biracial cohort =&gt; healthy offspring of patients with T2D =&gt; inverse association =&gt; adiponectinaemia (normal levels) =&gt; risk of incident prediabetes / diabetes =&gt; during longitudinal FU. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Initially normoglycaemic persons =&gt; increase 5ug/dl higher baseline plasma adiponectin level =&gt; 40% lower rate of progression =&gt; prediabetes / diabetes, 2.6 years of FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) 110 participants =&gt; end point (prediabetes) =&gt; 10 participants =&gt; progressed T2D (100 participants =&gt; prediabetes). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Well-known ethnic + geneder differences in plasma adiponectin levels =&gt; present study. Association of adiponectin status + incident prediabetes =&gt; consistent across gender + ethnicity =&gt; African-Americans (AA) + European-Americans (EA). =&gt; parental history T2D. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Point estimates =&gt; reduced risk for prediabetes =&gt; same order of magnitude in black + white offspring (0.44 + 0.48 respectively) =&gt; 95% CI wider in whites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Adjustment for BMI =&gt; increases adiponectin-associated OR =&gt; prediabetes from 0.48 =&gt; 0.61 + wider 95% Cl. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Observation =&gt; nominal redn = 40% in risk of incident prediabetes =&gt; despite adjustment for BMI =&gt; redn prediabetes risk assoc. with higher baseline adiponectin levels =&gt; partly mediated =&gt; adiposity related mechns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Previous cross-sectional + longitudinal studies =&gt; low adiponectin levels =&gt; increased risk of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Prospective Diabetes Prevention Programme (DPP) =&gt; patients with prediabetes =&gt; increased 3ug/ml baseline adiponectin levels =&gt; predicted 20-40% lower risk  =&gt; T2D in 3 year FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Approx 5ug/ml (1SD) higher baseline adiponectin levels =&gt; 40%lower risk of progression from normoglycaemia =&gt; prediabetes. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Association of adiponectin with diabetes risk =&gt; evident of earlier stage in the pathogenesis of dysglycaemia. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Ability =&gt; maintain high adiponectin prodn =&gt; protective of dysglycaemia in high risk of T2D. Hypoadiponectinaemia =&gt; risk factor  =&gt; initiation of early glucose abnormalities =&gt; predibetes / diabetes. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Favourable cardiometabolic profile of adiponectin =&gt; emerged since discovery.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N)  Mechns =&gt; not fully understood how adiponectin exerts it&#39;s favourable cardiometabolic effects. BUT could involve =&gt; improvement of insulin action, redn inflammatory tone, interaction with fibroblast growth factor (FGF)-21 + amelioration of lipotoxicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Rodent models =&gt; overexpression of adiponectin =&gt; several beneficial effects =&gt; increased metabolic flexibility, redn in inflammatory markers, redn steatosis, improved insulin sensitivity, redn apoptosis + preservation of B-cell function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Interaction between adiponectin + FGF21, a potent regulator of metabolism + energy utilization. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) FGF-21 =&gt; redn blood glucose levels + increased insulin sensitivity in mouse models of obesity + IR =&gt; upregulation of adiponectin expression. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) FGF-21 =&gt; clearance of toxic ceramides in obese animals + adiponectin-knockout mice =&gt; refractory to ceramide-lowering effects of FGF-21. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Adiponectin =&gt; critical mediator =&gt; favourable metabolic + insulin sensitizing effects FGF21. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Improvement in insulin sensitivity with PPAR-y agonists =&gt; mediated, in part =&gt; upregulation of adiponectin expression. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Intervention that increased adiponectin levels =&gt; attractive candidates =&gt; clinical trials =&gt; diabetes prevention + improvement =&gt; cardiometabolic health. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Interactions =&gt; increased adiponectin levels =&gt; exercise, weight loss, smoking cessation + treatment with PPAR-y agonists, PPAR-a agonists, ACE inhibitors + angiotensin 2 receptor blockers. All these interventions =&gt; favourable glucoregulatory outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Prediabetic participants =&gt; lifestyle intervention arm in DPP =&gt; increased circ adiponectin levels =&gt; 58% relative risk redn in incident diabetes vs placebo group. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Cross-sectional + longitudinal studies =&gt; low adiponectin levels =&gt; prevalent T2D, impaired glucose homeostasis =&gt; unfavourable cardiometabolic profile. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) AA&#39;s + EA&#39;s =&gt; parental history of T2D =&gt; enrolled in POP-ABC study, baseline adiponectin levels =&gt; inversely related =&gt; risk of incidient prediabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Predictive relationship evident =&gt; despite gender + ethnic differences in baseline adiponectin levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Interventions =&gt; increased adiponectin levels =&gt; protection against the risk of dysglycaemia regardless of gender or ethnicity. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) The mechanisms whereby adiponectin exerts its favorable cardiometabolic effects are not fully understood, but could involve improvement in insulin action, decreased inflammatory tone, interaction with fibroblast growth factor (FGF)-21 and amelioration of lipotoxicity, among others. (34–39) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="l data">Comparative study of glucose homeostasis, lipids and lipoproteins, HDL functionality, and cardiometabolic parameters in modestly severely obese African Americans and White Americans with prediabetes: implica</td>
<td class="l data">(A) African Americans (AA&#39;s) experience T2D + CV morbidity + mortality disproportionately more vs White Americans (WA&#39;s). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Exact contributions of obesity =&gt; T2D + CHD in AA&#39;s remain debatable. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Whether severe obesity =&gt; differentially modifies the metabolic mediators + precursor&#39;s of pre-diabetes + T2D + CVD in AA&#39;s + WA&#39;s =&gt; remains to be investigated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Increased epidemic of obesity =&gt; impact on glucose regulation, prediabetes + T2D =&gt; US ethnic + racial popns =&gt; comprehensive assessment of clinical + metabolic characteristics =&gt; modestly severe obese AA&#39;s vs WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) BMI &gt;30kg/m2 + prediabetes =&gt; &gt; Class III obesity + mean BMI &gt; 35kg/m2 + lean body fat &gt; 40% in both groups. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) BMI + % body fat greater in AA&#39;s vs WA&#39;s with prediabetes. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (g) Pathogenic Mechns =&gt; prediabetes, impaired glucose + T2D =&gt; abnormalities B-cell secretion, hepatic glucose prodn + glucose disposal (insulin-mediated [Si] + non-insulin-mediated [Sg + GEZI] glucose disposal) =&gt; prediabetes + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Abnormalities increase AA&#39;s vs WA&#39;s =&gt; increased IR (lower Si or higher HOMA-IR) + hyperinsulinaemia + hepatic glucose overprodn or hepatic IR =&gt; healthy non-obese + mildly obese AA&#39;s vs WA&#39;s. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Abnormalities come before development of prediabetes + T2D in AA&#39;s by decades. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Current study =&gt; modestly severely obese AA&#39;s =&gt; lower fasting + post glucose challenge serum glucose levels  vs WA&#39;s with prediabetes, BUT AA&#39;s have increased HbA1c levels vs WA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Current study =&gt; mean fasting + post challenge levels + corresponding serum insulin + C-peptide levels =&gt; lower in modestly severely obese AA&#39;s vs WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Previous study =&gt; mildly obese or overweight AA&#39;s =&gt; prediabetic subjects =&gt; prior poor B-cell function, (assessed by serum insulin + C-peptide levels). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Current study =&gt;  modestly severely obese AA&#39;s above point (L) =&gt; not the same. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Current study =&gt; serum insulin + C-peptide response =&gt; OGTT =&gt; corrected for prevailing glucose (insulinogenic index, insulin / glucose or C-peptide / glucose ratios) levels were similar in AA&#39;s + WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Use of FSIVGTT =&gt; examines in detail =&gt; B cell function + insulin sensitivity in modestly severely obese AA&#39;s vs WA&#39;s with prediabtes. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Modestly severely obese AA&#39;s with prediabetes =&gt; fairly well preserved B-cell function + ability to compensate =&gt; prevailing skeletal muscle IR vs WA&#39;s counterparts. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Obesity =&gt; major cause of IR in general popn + T2D =&gt; no significant differences in Si values =&gt; modestly severe obese AA&#39;s + WA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Previous studies =&gt; in vivo total body glucose disposal consists =&gt; insulin mediated (Si) + non-insulin-mediated or glucose-mediated (Sg or GEZI) glucose disposal. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Previous demonstrated =&gt; (Si) is lower + (Sg) is higher in healthy AA&#39;s with / without history of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Interesting that =&gt; higher Sg + GEZI values in obese AA&#39;s with prediabetes vs WA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Our data =&gt; greater Sg + GEZI values =&gt; important compensatory mechns =&gt; maintain normal / nearly normal glucose tolerance =&gt; modestly severely obese AA&#39;s with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Mechn =&gt; putative  greater Sg + GEZI values =&gt; remains to be elucidated in obese + non-obese AA&#39;s with / without prediabetes. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Typical lipid + lipoprotein profiles =&gt; assoc. =&gt; obesity, T2D, IR + metabolic syndrome =&gt; higher serum TG + lower HDL-C levels. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Insulin-resistant AA&#39;s =&gt; normal or higher HDL-C + apoA1 levels + lower serum TG levels vs WA&#39;s XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Current study =&gt; modestly severely obese, IR, AA&#39;s with prediabetes =&gt; sig. lower serum TG levels, normal / higher HDL-C level + HDL / TG ratio + apoA1 level vs WA&#39;s with similar IR (Si). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Our Findings =&gt; favourable lipid + lipoprotein profiles in obese + non-obese AA&#39;s =&gt; independent of degree of obesity =&gt; lower serum TG levels + normal / higher HDL-C + apoA1 levels in AA&#39;s + other blacks of African ancestry. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) HDL =&gt; important anti-atherogenic lipoprotein =&gt; several critical roles in lipid transport + atherogenesis . Anti-atherogenic function of HDL =&gt; PON1 activity =&gt; cosegregation with HDL in the circulation. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) PON1 =&gt; Inhibits oxidn of LDL, suppresses inflammation , improves endothelial function + injury repair (anti-apoptotic effect) + increased reverse cholesterol transport activity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Recent findings =&gt; PON1 activity =&gt; 50% redn in non-diabetic post menopausal AA women vs WA&#39;s =&gt; unexpected. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Our previously study =&gt; oxidised LDL + CRP levels =&gt; higher in non-diabetic, postmenopausal AA women vs WA&#39;s =&gt;  suggested that HDL was dysfunctional in AA&#39;s =&gt; play a critical role in atherogenesis in AA. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Our study =&gt; did not examine =&gt; potential effects of the severity of obesity =&gt; cardiometabolic markers in AA&#39;s + WA&#39;s with prediabetes. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Present study =&gt; modestly severely obese + prediabetes =&gt; PON1 + oxidized LDL levels =&gt; not different in WA&#39;s + AA&#39;s =&gt; surprising + unexpected =&gt; further examined =&gt; qualitative functions of HDL =&gt; subclinical inflammation CRP + adipocytokines (IL-6). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Previous studies =&gt; increased CRP levels in obese AA&#39;s vs WA&#39;s XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) Current study =&gt; CRP + IL-6 levels =&gt; not statistically significant =&gt; modestly severely obese AA&#39;s with prediabetes vs WA&#39;s. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M1) Serum adiponectin =&gt; (very potent adipose derived insulin sensitizer) =&gt; redn rates of T2D, metabolic syndrome + CAD. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N1) Serum adiponectin levels =&gt; redn in AA&#39;s + patients with obesity + IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O1) Current study =&gt; adiponectin levels =&gt; lower BUT not significantly different =&gt; modestly severely obese AA&#39;s vs WA&#39;s with prediabetes. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P1) Mechns =&gt; unknown =&gt; adaptive metabolic processes associated with severe degree of obesity =&gt; partly responsible. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q1) Several metabolic paradoxes in modestly severely obese AA&#39;s with prediabetes vs WA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R1) Modestly severely obese AA&#39;s + WA&#39;s with prediabetes =&gt; similar glucose responses + Si values =&gt; BUT req&#39;d diverse regulatory mechns. XXX X</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="l data">Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins</td>
<td class="l data">(A) W-3-PUFA&#39;s alleviates obesity induced IR + advanced hepatic steatosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Beneficial effects of W-3-PUFA&#39;s =&gt; upregulation of genes involved in insulin sensitivity (IS) =&gt; PPAR-y, glucose transport =&gt; GLUT-2 + GLUT-4, insulin receptor signalling =&gt; IRS-1 + IRS-2 in both adipose tissue + liver. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Also expression + prodn of potent anti-inflammatory, anti-steatotic + insulin sensitizing adipokine =&gt; adiponectin + induced phosphorylation of AMPK. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Decrease in W6-PUFA-derived eicosanoids (PGE2 + 5-HETE) + increased prodn of =&gt; protective W3-PUFA-derived lipid mediators (protectins + resolvins) =&gt; mimicked insulin sensitizing + anti-steatotic effects of W3-PUFA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Effects of resolvins + protectins more potent than their W-3-PUFA precursors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) W-3-PUFA&#39;s =&gt; reduced formation of eicosanoids from 5-lipoygenase pathway of arachidonic acid metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) The 5-lipoxygenase pathway is an established potent steatogenic factor in obese mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Inhibition of arachidonic acid derived eicosanoids =&gt; increased synthesis of bioactive intermediaries from W-3-PUFA&#39;s =&gt; 17-HDHA, resolvin D1, + protectin D1, BUT not resolvin E1 (because resolvin E1 &lt; limit of detection from our samples). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) These oxygenated products of W-3-PUFA&#39;s =&gt; evoked potent protective actions =&gt; in nanomolar + picomolar ranges =&gt; resolution of unremitting inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Obesity =&gt; low grade inflammation. W-3-PUFA&#39;s =&gt; lipid mediators (protectins + resolvins) =&gt; resolution of local inflammation =&gt; underlie beneficial effects of these compounds on IR + hepatic steatosis. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Current study =&gt; strong support =&gt; increased intake of W-3-PUFA&#39;s =&gt; prevent metabolic liver disease + similar to the improved outcomes reported in arthritis, cystic fibrosis, IgA nephropathy, diabetes, ulcerative colitis, Crohn&#39;s disease, asthma + sepsis. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Sum of the findings in the current study + reported literature =&gt; W-3-PUFA&#39;s =&gt; reduce incidence of necroinflammatory liver injury: strong rationale for dietary supplementation with W-3-PUFA&#39;s in patients with liver disease. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) W-3-PUFA&#39;s dietary supplementation could be given to marginal steatotic liver donors, currently excluded due to presence of macrovesicular steatosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Cannot distinguish between recruited and resident macrophages. Does Resolvin E1 decrease macrophage infiltration, or does this lipid mediator affect Kuffer cells (liver resident macrophages)? XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="l data">Insulin resistance and body fat distribution in South Asian men compared to Caucasian men</td>
<td class="l data">(A) This study =&gt; compared characteristics of body fat content + distribution between South Asian (SA) + Caucasian (CA) men with similar BMI, + functional characteristic of adipose tissue, esp. related to insulin sensitivity (IS). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) BMI, WAIST CIRCUMFERENCES (WC) and % TOTAL BODY FAT =&gt; for a given BMI or WC =&gt; SA men had 6% higher total body fat then CA men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Findings =&gt; threshold for obesity in SA&#39;s approx. 2kg/m2 lower vs CA&#39;s. A WC of 10cm lower in SA&#39;s confers a similar estimate of % body fat. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Discrepancies =&gt; indicative of body fat content =&gt; adjustments required for BMI or WC to define obesity =&gt; did not entirely account for possible differences in inherent IR in the SA popn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) ETHNIC DIFFERENCES IN VISCERAL FAT =&gt; did not find that SA&#39;s preferentially deposit fat in visceral adipose tissue, despite SA&#39;s having higher % body fat, =&gt; did not have a higher absolute amount or % of total fat as visceral fat. Particularly evident =&gt; two groups were matched for % body fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Ratio&#39;s of intraperitoneal fat / abdominal subcutaneous fat higher in CA men vs SA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Ratio&#39;s observed in CA&#39;s are similar to those reported for a large popn of CA men =&gt; Dallas Heart Study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (H) Lower ratio&#39;s =&gt; not prone to preferential deposition of body fat in the visceral compartment =&gt; unlikely =&gt; increased IR found in SA&#39;s =&gt; explained by preferential accumulation of visceral fat. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) TRUNCAL SKINFOLDS AND HIP CIRCUMFERENCE =&gt; In spite of higher % body fat for a given BMI in SA&#39;s  =&gt; no differences in hip circumferences between the two groups, or in waist-to-hip ratios. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Truncal skinfolds thicknesses increase in SA&#39;s =&gt; implies that SA&#39;s =&gt; preferential accumulation in truncal fat vs gluteofemoral fat. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) If SA&#39;s have preference for body fat compartmentalization =&gt; it is for truncal subcutaneous fat + not visceral fat =&gt; finding consistent with previous reports =&gt; shown strong relationship between subcutneous fat + IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Shown for the 1st time =&gt; truncal skinfolds =&gt; predict % total body fat independent of ethnicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) ADIPOCYTE SIZE =&gt; potentially important finding =&gt; in this study =&gt; SA&#39;s had larger abdominal subcutaneous adipocytes vs CA&#39;s =&gt; this is true =&gt; when the two groups were compared at similar body fat contents. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Growing body of evidence =&gt; large adipocytes are dysfunctional =&gt; they predict IR + T2D independent of obesity. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Enlarged subcutaneous abdominal adipocyte size, BUT not obesity itself =&gt; predicts T2D independent of IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Genetic factors influencing adipocytes size =&gt; play a role in IR. Even if a predisposition to IR observed in SA&#39;s =&gt; cannot be attributed to preferential accumulation of visceral fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) The question can still be asked  =&gt; whether all the excess IR observed in SA popn =&gt; can be explained =&gt; hidden high body-fat content =&gt; or perhaps =&gt; excess of truncal subcutaneous fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Shown previously =&gt; increased body fat content =&gt; progressively lower insulin-mediated glucose disposal rates =&gt; likely that increased IR observed in SA&#39;s =&gt; explained by &quot;hidden&quot; obesity =&gt; excess body fat content NOT seen with standard BMI or WC measurements + increased possibility =&gt; predisposition for deposition of fat in the trunk accentuates IR. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Previous studies =&gt; truncal fat =&gt; metabolically more active vs lower body fat =&gt; if so =&gt; maldistribution of body fat in SA&#39;s =&gt; contributes significantly =&gt; increase IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) This study =&gt; evidence that supports =&gt; preferential accumulation of truncal fat in SA&#39;s =&gt; + metabolic profile =&gt; predisposes to IR + T2D. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Large adipocytes =&gt; consistent with previous studies =&gt; &quot;dysfunctional&quot; characteristics of large cells. Our study =&gt; abdominal adipose size =&gt; inversely correlated =&gt; glucose disposal rates + adiponectin levels. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Subgroups were matched for % body fat, adipocytes size =&gt; still significantly greater in SA&#39;s + glucose disposal rates + adiponectin levels reduced + leptin levels increase in SA&#39;s =&gt; confirming previous reports. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Current study =&gt; insights =&gt; for a given BMI, WC or waist-to-hip ratio =&gt; increase % total body fat is CA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Preferentially accumulate body fat in truncal (+ abdominal) subcutaneous adipose tissue =&gt; NOT in visceral adipose tissue =&gt; this maldistribution of body fat =&gt; metabolic abnormalities beyond total body fat. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) SA =&gt; increased adipocytes, increased NEFFA + redn adiponectin =&gt; dysfunctional adipose tissue =&gt; role in metabolic abnormalities beyond total + truncal fat. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) SA men vs CA men =&gt; increase % total fat for a given BMI + preferentially accumulate this fat in truncal adipose tissue. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) There is no accumulation of intraperitoneal fat, truncal adipose tissue in SA&#39;s =&gt; abnormally large adipocytes =&gt; likely are dysfunctional =&gt; as shown by high levels of NEFA + low levels of adiponectin. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Abnormalities in adipose tissue =&gt; contribute importantly to increase IR observed in SA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) The major limitation of this study is the number of subjects investigated. The number was limited by the complexities of the metabolic and imaging studies. For this reason, addition studies are needed to confirm our conclusions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="l data">Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study</td>
<td class="l data">(A) This prospective study =&gt; strong association =&gt; clinical raised ferritin (below the range indicative of clinical haemochromatosis) + development of incident diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) The risk =&gt; elevated 7-fold =&gt; clinically raised ferritin group vs lowest ferritin category. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Association =&gt; potential importance =&gt; understanding the aetiology  of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Our study =&gt; new information =&gt; association of serum ferritin + incident T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Unlike previous studies =&gt; study the assocation =&gt; men + women in the same prospective study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Strong assocations of clinically raised ferritin with diabetes vs whole group of those with normal ferritin + also vs those in the low quartile of ferritin distribution. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Our sensitivity analysis =&gt; this was regardless of the cut-point of the upper limit of ferritin in women =&gt; debate whether the threshold should be 150, 200 or the same as men at 300 ng/ml. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Elevated ferritin =&gt; predictive of diabetes independently of a comprehensive range of risk factors + confounders =&gt; previous studies =&gt; only limited no risk factors accounted for. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Elevated ferritin =&gt; associated with diabetes independently of known risk factors for diabetes =&gt; (age, BMI, sex, family history, physical inactivity + smoking) + dietary factors + EtOH intake =&gt; measured by food diary. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Accounting for potential confounding effect of 3 markers of inflammation (IL-6 + fibrinogen + CRP (measure is previous studies)). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Accounted for potential confounding effect of hepatic enzymes + adiponectin =&gt; both associated with incident diabetes BUT association with ferritin is unclear. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (l) Data on fasting glucose =&gt; not available in EPIC-Norfolk study, BUT suggest non-diabetic hyperglycaemia =&gt; likely to be on the causal pathway, it is not likely to be a confounder of the ferritin-diabetes association. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Mechn of the association =&gt; ferritin + T2D =&gt; not established BUT iron deposition in the liver =&gt; may cause IR =&gt; interfering with the ability of insulin to suppress hepatic glucose prodn. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Iron =&gt; auto-oxidised =&gt; highly reactive, lipid-soluble iron-oxygen complexes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) These free radicals are powerful pro-oxidants =&gt; change membrane properties + result in tissue damage. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Oxidative stress =&gt; hyperglycaemia =&gt; disturbed glucose metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) In addition iron accumulation in hepatocytes =&gt; interfere with the insulin extracting capacity of the liver =&gt; affect insulin synthesis + secretion in the pancreas. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Iron excess =&gt; contributes initially to IR + subsequently to decreased insulin secretion. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Independent asssociation of hepatic enzymes + incident diabetes =&gt; well described. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Strong +ve correlation =&gt; ferritin + hepatic enzymes =&gt; ALT + GGT (r = 0.29 + r = 0.37, p &lt;0.0001, respectively). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Consistent =&gt; recent reports =&gt; correlation of 0.37 (p &lt; 0.001) between ALT + serum ferritin =&gt; 959 women =&gt; cross-sectional Korean study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) It is plausable =&gt; iron overload in the liver damages hepatocytes =&gt; elevated transaminases + GGT. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) No access to liver ultrasound or biospy in our study =&gt; correlation between ferritin level + NAFLD or NASH =&gt; associated with elevated ALT =&gt; in obese + mainly non-obese individuals. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Association =&gt; raised hepatic iron concn + severity of fibrosis in NASH =&gt; also reported. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Recent study =&gt; association between hepatic fat content =&gt; measured by computed tomography + ferritin concn =&gt; diabetic individuals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Hypo-adiponectinaemia =&gt; predictive of future diabetes =&gt; no previous reports =&gt; association between serum ferritin + adiponectin levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) CONCLUSIONS =&gt; shown prospectively =&gt; modestly elevated ferritin, below levels diagnostic of haemochromatosis or other iron-storage disorders =&gt; predicts incident diabetes independently of known risk factors + confounders. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) We report a strong negative correlation between adiponectin and ferritin (r −0.21 to −0.28, p&lt;0.0001). Although the mechanism underlying this association is not clear, it is plausible that it works through the recently described association of ferritin with abdominal fat [31]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) These findings have implications for increasing our understanding of the aetiology of type 2 diabetes and merit further study in future studies that help to clarify causality and advance this area of research. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="l data">Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men</td>
<td class="l data">(A) These studies =&gt; prevalence of IR in healthy, young lean Asian-Indian (AI) men =&gt; 3 - 4 fold greater than lean men in other ethnic group. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) When adjusted for the (insulin sensitivity index) ISI, this increased prevalence of IR in AI men =&gt; 2-fold increased in (hepatic tri-glyceride) HTG content + plasma IL-6 concn vs Caucasian (CA) men. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) In contrast =&gt; no differences in the prevalence of IR among AI women vs other ethnic groups =&gt; potentially important protective role of oestrogen in this process. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Increased evidence =&gt; causal relationship between hepatic steatosis + hepatic IR =&gt; rodent models with hepatic steatosis + patients NAFLD. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Short-term high fat feeding in rats =&gt; hepatic steatosis + hepatic IR =&gt; reversed post-treatment with =&gt; mitochonrial uncoupling agent 2, 4-dinitrophenol. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Comparable results =&gt; patients with severe lipodystrophy =&gt; chronic leptin treatment therapy =&gt; reverse their hepatic steatosis + hepatic IR. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Rosiglitazone treatment =&gt; patients with T2D =&gt; lower HTG content + ameliorate hepatic IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Recent studies =&gt; relatively small weight loss (~8kg) =&gt; patients with poorly controlled T2D =&gt; reversed =&gt; hepatic steatosis + normalised fasting plasma glucose concns + rates of hepatic glucose prodn + hepatic insulin responsiveness. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Molecular mechn of fat-induced hepatic IR is unclear =&gt; recent studies =&gt; rodents =&gt; intracellular increase in diacyl glycerol (DAG) =&gt; activates protein kinase Ce =&gt; activates a serine kinase cascade =&gt; blocks insulin stimulation of IRS-2 tyrosine phosphorylation =&gt; early step in insulin signalling. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX STEPS OF INSULIN SIGNAL TRANSDUCTION: XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) Insulin binds to insulin receptor. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) Insulin receptor is activated by autophosphorylation of tyrosine residues which attracts IRS-1. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (3) IRS-1 attracts p85 + PI-3 kinase. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (4) PI-3 kinase is activated + phosphorylates PIP2 to form PIP3 XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (5) PI-3 attracts both AKT + PDK-1, PDK-1 phosphorylates + activates AKT. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (6) Active AKT phosphorylates + inactivates GSK-3. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (7) Insulin generates signals via PI-3K which activates protein phosphatase-1 dephosphorylates and activates glycogen synthase. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (8) AKT generates signals which trigger translocation of GLUT4 to the plasma membrane which facilitates glucose uptake. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Recent studies =&gt; visceral adiposity =&gt; role =&gt; hepatic IR =&gt; release of FA&#39;s + adipocytokines to the liver =&gt; via the portal vein. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) No differences =&gt; circulating concns =&gt; adiponectin or TNF-a between AI men vs CA men =&gt; suggesting =&gt; adipocytokines =&gt; not likely playing a major role in causing increased prevalence of IR in the AI men. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) In contrast =&gt; ~2 fold increase plasma IL-6 concns in the AI men =&gt; persisted after adjustment for the ISI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Recent studies in Rodents =&gt; acute infusions of IL-6 =&gt; IR in liver + skeletal muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) The increase IL-6 concn =&gt; playing a causative role =&gt; increased prevalence of IR in AI men OR secondary =&gt; hepatic steatosis + IR =&gt; remains to be determined. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Assessed B-cell function =&gt; subgroup of AI men vs CA men =&gt; ~30% increase in basal cell responsibility (Phib) =&gt; AI men vs CA men. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Compensatory increase in B-cell function =&gt; inadequate for the degree of IR =&gt; reflected by 60% redn in the disposition index in AI men. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Prevalence of IR =&gt; 3 - 4 fold higher in young, lean, healthy AI men vs men of other ethnic groups + increase in prevalence in IR in the AI men  =&gt; assoc. with increased HTG content + plasma IL-6 concns. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Increased prevalence of NAFLD in AI men =&gt; important implications for future health risks, because this condition =&gt; NAFLD =&gt; assoc. with steatohepatitis =&gt; progress to cirrhosis + end stage liver disease. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Significant ethnic differences =&gt; pathogenesis of IR between AI men vs CA men =&gt; important therapeutic implications for prevention + treatment of T2D in the ethnic group + possibly explain the lower efficacy of lifestyle intervention in the Indian diabetes prevention study vs US + Finnish diabetes prevention study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Whether this increase in plasma IL-6 concentration is playing a causative role for the increased prevalence of insulin resistance in the Asian-Indian men or is secondary to the hepatic steatosis and insulin resistance remains to be determined. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="l data">Lipids and glucose in type 2 diabetes: what is the cause and effect?</td>
<td class="l data">(A) Initial perception that a disorder of glucose metabolism was the primary event in the pathogenesis of T2D, =&gt; growing appreciation =&gt; chronic increase FFA levels =&gt; early event that contributions =&gt; development of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) FFA&#39;s =&gt; induce IR =&gt; increase FFA levels =&gt; can be a beneficial adaptive response during starvation + pregnancy. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) IR =&gt; can become counterproductive  when there is excess energy intake assoc. =&gt; physical inactivity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Extra fuel =&gt; stored in visceral + subcutaneous fat depots =&gt; as fat accumulates =&gt; ongoing increase in the levels of plasma FFA&#39;s =&gt; causes IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Deficit of a product of adipose tissue =&gt; adiponectin =&gt; contribute to increase IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) To counter IR + prevent hyperglycaemia =&gt; increase insulin levels. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Individuals with genetic predisposition for T2D =&gt; pancreas cannot compensate for the increased secretory demands placed on it =&gt; T2D. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Pivotal role =&gt; FFA&#39;s =&gt; IR + T2D =&gt; optimal therapeutic intervention =&gt; redn plasma FFA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) PPAR family =&gt; intimately involved in lipid metabolism. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Two subtypes of these receptors =&gt; PPAR-a + PPAR-y. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) PPAR-a =&gt; increased FA oxidn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) PPAR-y =&gt; redistribution of fat from visceral to subcutneous body fat + increased adiponectin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Outcome of activation of PPAR-y =&gt; redn plasma FFA concns + improved insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Effects of PPAR-a on lipid metabolism =&gt; increase insulin sensitivity. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) PPAR agonists =&gt; selectively activate either PPAR-a (e.g. fibrates) OR PPAR-y (eg. T2D&#39;s) =&gt; improve lipid metabolism. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Dual agonism =&gt; PPAR-a/y agonists =&gt; addition benefits above + beyond those achieve through individual action on either PPAR-a or PPAR-y. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) It may be that dual agonism with PPAR-a/Y agonists will provide additional benefits above and beyond those achieved with sole activation of either PPAR-a or PPAR-Y.</td>
</tr>
</tbody>
</table>
</div>
</div>
<br>
</div>
</body>
</html>
